3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
45
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrence
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Inflammatory Breast Neoplasms
1
HER2 Positive Breast Cancer
1
Genomic Instability
1
Cholangiocarcinoma
1
Breast Cancer Metastatic
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
pertuzumab
1
pazopanib
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Injections, Subcutaneous
1
Focus Groups
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts